458 related articles for article (PubMed ID: 25981607)
21. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
[TBL] [Abstract][Full Text] [Related]
22. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.
McBane RD; Loprinzi CL; Zemla T; Tafur A; Sanfilippo K; Liu JJ; Garcia DA; Heun J; Gundabolu K; Onitilo AA; Perepu U; Drescher MR; Henkin S; Houghton D; Ashrani A; Billett H; McCue SA; Lee MK; Le-Rademacher JG; Wysokinski WE;
J Thromb Haemost; 2024 Jun; 22(6):1704-1714. PubMed ID: 38537780
[TBL] [Abstract][Full Text] [Related]
23. Changing Treatment Patterns in Patients With Venous Thromboembolism in Taiwan.
Lee CH; Fang CC; Tsai LM; Lin HW; Chen PS; Lin SH; Li YH
Circ J; 2020 Jan; 84(2):283-293. PubMed ID: 31932560
[TBL] [Abstract][Full Text] [Related]
24. Apixaban: A Review in Venous Thromboembolism.
Greig SL; Garnock-Jones KP
Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
[TBL] [Abstract][Full Text] [Related]
25. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
[TBL] [Abstract][Full Text] [Related]
26. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Imberti D; Gallerani M; Manfredini R
J Thromb Thrombolysis; 2012 Aug; 34(2):208-13. PubMed ID: 22466929
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
29. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
[TBL] [Abstract][Full Text] [Related]
30. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
31. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
32. A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention.
Gumprecht J; Domek M; Lip GYH
Expert Opin Drug Saf; 2019 Dec; 18(12):1119-1125. PubMed ID: 31580164
[No Abstract] [Full Text] [Related]
33. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
Weitz JI; Segers A; Raskob G; Roberts RS; Francis C; Lassen MR; Fuji T; Swaim RM; Lee M; Peters G; DiBattiste PM; Tesfaye F; Strony J
J Thromb Haemost; 2019 Dec; 17(12):2081-2088. PubMed ID: 31529590
[TBL] [Abstract][Full Text] [Related]
34. Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants.
Turagam MK; Velagapudi P; Bongu N; Chinnakotla B; Kocheril A
Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):139-47. PubMed ID: 26126820
[TBL] [Abstract][Full Text] [Related]
35. Quick reference guide to apixaban.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
[TBL] [Abstract][Full Text] [Related]
36. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
37. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
38. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.
Akl EA; Kahale L; Terrenato I; Neumann I; Yosuico VE; Barba M; Sperati F; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006466. PubMed ID: 24980743
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
[TBL] [Abstract][Full Text] [Related]
40. Apixaban for extended treatment of venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Porcari A; Raskob GE; Weitz JI;
N Engl J Med; 2013 Feb; 368(8):699-708. PubMed ID: 23216615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
